IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02273984.html
   My bibliography  Save this paper

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Author

Listed:
  • Christos Chouaid

    (CIC - Biotherapie - CHU Henri Mondor - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - INSERM - Institut National de la Santé et de la Recherche Médicale - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, CRETEIL - Pneumologie - Service de Pneumologie - CHI Créteil, U955 Inserm - UPEC - IMRB - CEPIA/"Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health" [Créteil] - IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12)

  • Lionel Bensimon

    (MSD - Merck Sharp & Dohme Corp. - Whitehouse Station)

  • Emilie Clay

    (Evaluation des systèmes de soins et santé perçue - Université de la Méditerranée - Aix-Marseille 2, Creativ-Ceutical France - Creativ-Ceutical)

  • Aurélie Millier

    (Creativ-Ceutical France - Creativ-Ceutical, Creativ-Ceutical - Creativ-Ceutical SARL)

  • Laurie Levy-Bachelot

    (MSD - Merck Sharp & Dohme Corp. - Whitehouse Station)

  • Min Huang

    (Merck & Co. Inc - Merck Sharp and Dohme)

  • Pierre Lévy

    (LEDa - Laboratoire d'Economie de Dauphine - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique)

Abstract

No abstract is available for this item.

Suggested Citation

  • Christos Chouaid & Lionel Bensimon & Emilie Clay & Aurélie Millier & Laurie Levy-Bachelot & Min Huang & Pierre Lévy, 2019. "Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in F," Post-Print hal-02273984, HAL.
    • Handle: RePEc:hal:journl:hal-02273984
    DOI: 10.1016/j.lungcan.2018.11.008
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Michaela Carla Barbier & Esther Pardo & Cédric Michael Panje & Oliver Gautschi & Judith Eva Lupatsch, 2021. "A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerl," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 669-677, July.
    2. Haiying Ding & Wenxiu Xin & Yinghui Tong & Jiao Sun & Gaoqi Xu & Ziqi Ye & Yuefeng Rao, 2020. "Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 15(9), pages 1-16, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02273984. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.